Search for: "SCHERING-PLOUGH"
Results 341 - 360
of 404
Sort by Relevance
|
Sort by Date
21 Jan 2008, 4:45 pm
Merck and Schering-Plough's press release stated that Zetia not only failed to slow down the accumulation of fatty plaque in the arteries, it contributed to the formation of plaque. [read post]
21 Jan 2008, 6:51 am
No damages payout, just governance reforms in Schering-Plough shareholder suit, but lawyers to get $9.5 million anyway [NJLJ/Ted at Overlawyered] Getting the Supreme Court's message? [read post]
19 Jan 2008, 1:05 am
See In re Schering-Plough Corp., FTC File No. 071-0132. [read post]
16 Jan 2008, 11:04 am
It is jointly marketed by Merck and Schering-Plough. [read post]
16 Jan 2008, 5:38 am
[New Jersey Law Journal/law.com; In re Schering-Plough Corp. [read post]
15 Jan 2008, 10:46 pm
Congressman Bart Stupak said, "It is easy to conclude that Merck and Schering-Plough iintentionally sought to delay the release of this data.Source here. [read post]
15 Jan 2008, 12:02 am
Plaintiffs Lawyers Split $9.5M Fee in Shareholder Suit Against Schering-Plough
New Jersey Law Journal
A federal judge approved a settlement Monday in a shareholders' derivative suit against Schering-Plough Corp. with no award of damages but a $9.5 million fee to plaintiffs counsel and a company pledge to reform its governance. [read post]
14 Jan 2008, 8:49 am
This drug-safety issue received renewed attention in December 2007 when an article in The New York Times suggested that Merck and Schering-Plough, in fact, knew about these Zetia side effects but that this information was withheld by the drug companies. [read post]
8 Jan 2008, 6:22 am
Drug makers Merck and Schering-Plough never published the results of studies regarding Zetia, an anti-hyperlipidemic drug often prescribed to lower cholesterol levels. [read post]
10 Dec 2007, 3:41 am
Both drug are marketed and sold by Schering-Plough and Merck.Cardiologists have been demanding Schering-Plough and Merck come forward with clinical trials to prove the drugs' effectiveness and safety. [read post]
29 Nov 2007, 2:29 pm
FDA staffers said no date for the meeting has been set.Those "other" asthma drugs to be consider at this future FDA meeting would be GSK's Advair and Foradil, made by Novartis AG (NVS) and sold in the U.S. by Schering-Plough Corp.As for the suggestion that Serevent and Advair should be recalled from the market, this idea was rejected by an FDA official and a GSK representative. [read post]
27 Nov 2007, 8:05 am
Merck and Schering-Plough attempted to pacify critics most recently by committing to release a portion of the data from their joint clinical trial next March. [read post]
26 Nov 2007, 3:06 pm
The October 2007 FDA staff report was prepared in advance of a meeting of an advisory panel of pediatricians later this week being convened to consider the safety of Serevent and Advair (made by GlaxoSmithKline PLC), both of which contain the active ingredient salmeterol, as well as another asthma drug, Foradil (made by Novartis AG and marketed in the U.S. by Schering-Plough Corp.), which contains the active ingredient formoterol. [read post]
2 Nov 2007, 6:37 am
” In re Schering Marketing & Sales Prac. [read post]
12 Oct 2007, 7:03 am
Schering-Plough Corp., 2006 WL 2546494, at *2 (E.D. [read post]
7 Sep 2007, 8:52 am
Schering-Plough, Coca-Cola, Bristol-Myers Squibb, and Prudential Financial were among the companies receiving inquiries, The Wall Street Journal reported. [read post]
6 Sep 2007, 12:08 pm
Schering-Plough Corp., 367 N.J. [read post]
31 Aug 2007, 1:35 am
"
Schering-Plough Defends Suits Over Marketing of 'Off-Label' Drug Uses "Schering-Plough Corp. faces a spate of federal court litigation over promotion of its drugs for uses not approved by the Food and Drug Administration. [read post]
31 Aug 2007, 12:53 am
Schering-Plough Defends Suits Over Marketing of 'Off-Label' Drug Uses
New Jersey Law Journal
Schering-Plough Corp. faces a spate of federal court litigation over promotion of its drugs for uses not approved by the Food and Drug Administration. [read post]
2 Aug 2007, 4:41 am
The pharmaceuticals maker Schering-Plough said Thursday it plans to sell 50 million common shares and $2.5 billion in mandatory convertible preferred stock in a public offering. [read post]
